Search Results
Your search for Matthew S matches 1058 pages
Showing 1051 - 1058Particulate Matter Air Pollution Contributes to Increased Risk of Lung Cancer in Europe
Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...
Female Survivors of Childhood Cancer Have Increased Risk of Infertility
Decreased pregnancy rates and early menopause have been reported in female cancer survivors, although there is less information on infertility rates and reproductive interventions in these patients. In a study reported in Lancet Oncology, Sara E. Barton, MD, of Brigham and Women’s Hospital...
Majority of Patients with Incurable Lung Cancer Have Inaccurate Expectations about Goals of Radiation Therapy
Aileen B. Chen, MD, MPP, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium recently assessed patient expectations regarding goals of radiation therapy (RT) for incurable lung cancer. They ...
Study Reveals Abstracts with Financial Conflicts of Interest Have Higher Meeting Prominence, Better Peer Review Score
Beverly Moy, MD, Clinical Director of the Breast Oncology Program at Massachusetts General Hospital, and colleagues recently analyzed the relationship between declaration of financial conflicts of interest and "research prominence" for abstracts presented at American Society of Clinical Oncology...
Lugano 2013: Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion
The 17p deletion in chronic lymphocytic leukemia (CLL) is associated with worse outcome in patients receiving standard chemotherapy. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown durable antitumor activity in high-risk CLL. Adrian Wiestner, MD, PhD, of the National...
BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...
High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...
Cryoablation Spot Treats Cancer in the Lung, Extends Survival
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
